Eli Lilly And Co vs Clear Secure Inc — how do they compare? Eli Lilly And Co trades at $1,160.05 (market cap $1.02T), while Clear Secure Inc trades at $56.86 (market cap $5.76B). The key difference: Eli Lilly And Co is far larger — about 177.1× Clear Secure Inc's market cap, and Clear Secure Inc pays the higher dividend (1.05%). Which is the better fit depends on your goals.
| LLY | YOU | |
|---|---|---|
Market Cap | $1.02T | $5.76B |
Sector | Health | Technology |
52-Week High | $1.24K | $62.36 |
52-Week Low | $625.65 | $28.84 |
Enterprise Value | $1.06T | $5.07B |
Dividend Yield | 0.6% | 1.05% |
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,150.86, down 2.39% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $8.55 exceeding expectations by 23%. Revenue surged to $65.18 billion in 2025, driving a net income margin of 34.99%. Recent news highlights LLY's $2.8 billion acquisition of AtaiBeckley to expand its neuroscience pipeline, signaling strategic growth in mental health treatments.
Outlook remains positive with analyst consensus price target of $1,380 implying 20% upside, supported by 73% buy ratings. Key risks include high valuation multiples (P/E 41.89) and rising debt levels, though operating cash flow growth to $16.81 billion in 2025 provides financial flexibility. Investors should monitor Q2 2026 earnings on August 5 for continued execution on weight-loss drug demand and integration of recent acquisitions.
Clear Secure (YOU) trades at $57.18, up 2.05% with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with 65.48% gross margins and impressive 81.15% ROE, though valuation multiples remain elevated with a P/E of 44.82. Recent earnings beat expectations in Q1 2026 with $0.38 EPS versus $0.35 expected, while analyst sentiment remains divided with equal buy/hold ratings.
The stock presents growth potential with expanding revenue and profitability, but faces valuation concerns and competitive pressures. Key catalysts include continued airport expansion and AWS partnership, while risks involve execution challenges and market volatility. The consensus price target of $56.67 suggests limited near-term upside from current levels.
Trailing returns across standard periods
Latest headlines on both assets
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →Clear Secure operates a secure identity platform that uses biometrics—specifically eyes, face, and fingerprints—to automate and expedite identity verification. While its most visible application is the CLEAR Plus airport subscription service, the company functions as a broad-based identity layer for travel, healthcare, and digital services, aiming to replace physical IDs with a secure, biometric link.
Read more on YOU →